Pluvicto had sales of just under $1Bil last year, just missing official blockbuster drug status, Novartis predicts peak sales of $2Bil per annum.
The expectation is(from the above analysis), our product will compete head to head with it. Just one of many potential revenue opportunities for Clarity.
Our small molecule binding agent works better than anything else judging by the imaging results so far.
Sounds v good to me.
CU6 - Media and Industry News, page-3
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.35 |
Change
0.220(5.33%) |
Mkt cap ! $1.352B | |||
| Open | High | Low | Value | Volume |
| $4.10 | $4.35 | $4.05 | $7.494M | 1.770M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2555 | $4.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.35 | 5589 | 4 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.25 |
Change
0.220 ( 3.26 %) |
||||
| Open | High | Low | Volume | ||
| $4.09 | $4.31 | $4.09 | 45313 | ||
| Last updated 15.58pm 24/05/2024 ? | |||||
| CU6 (ASX) Chart |